159 related articles for article (PubMed ID: 28949997)
21. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
[TBL] [Abstract][Full Text] [Related]
22. Long term evaluation of etiological treatment of chagas disease with benznidazole.
Cancado JR
Rev Inst Med Trop Sao Paulo; 2002; 44(1):29-37. PubMed ID: 11896410
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions.
Correia JPR; Costa ACD; Rocha EA; Quidute ARP; Cândido DDS; Ponciano ÂMS; Fonteles MMF; Oliveira MF
Rev Soc Bras Med Trop; 2017; 50(3):334-340. PubMed ID: 28700051
[TBL] [Abstract][Full Text] [Related]
24. Arthritis and benznidazole: more closely related than we thought.
Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
[TBL] [Abstract][Full Text] [Related]
25. Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Villar JC; Reidel S; Gibbons L; Sosa-Estani S
Trop Med Int Health; 2023 Jan; 28(1):2-16. PubMed ID: 36420767
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
[TBL] [Abstract][Full Text] [Related]
27. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.
Carrilero B; Murcia L; Martínez-Lage L; Segovia M
Rev Esp Quimioter; 2011 Sep; 24(3):123-6. PubMed ID: 21947093
[TBL] [Abstract][Full Text] [Related]
28. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.
Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M
J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903
[TBL] [Abstract][Full Text] [Related]
30. Adverse systemic reaction to benznidazole.
Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH
Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820
[TBL] [Abstract][Full Text] [Related]
31. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.
Aldasoro E; Posada E; Requena-Méndez A; Calvo-Cano A; Serret N; Casellas A; Sanz S; Soy D; Pinazo MJ; Gascon J
J Antimicrob Chemother; 2018 Apr; 73(4):1060-1067. PubMed ID: 29351667
[TBL] [Abstract][Full Text] [Related]
32. Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.
Crespillo-Andújar C; Venanzi-Rullo E; López-Vélez R; Monge-Maillo B; Norman F; López-Polín A; Pérez-Molina JA
Drug Saf; 2018 Nov; 41(11):1035-1048. PubMed ID: 30006773
[TBL] [Abstract][Full Text] [Related]
33. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
[TBL] [Abstract][Full Text] [Related]
34. Should benznidazole be used in chronic Chagas' disease?
Bestetti RB
Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760
[No Abstract] [Full Text] [Related]
35. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
[TBL] [Abstract][Full Text] [Related]
36. Benznidazole treatment reduces the induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity in Chagas disease symptomatic patients.
Marañón C; Egui A; Fernández-Villegas A; Carrilero B; Thomas MC; Segovia M; López MC
Parasite Immunol; 2013; 35(5-6):180-7. PubMed ID: 23473453
[TBL] [Abstract][Full Text] [Related]
37. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
38. [Benzonidazole: one of the rare treatment for Chagas disease].
Coilliot C; Rouault M; Wolf A; Boulliat C; Beranger C; Gaillard K; Oliver M
Med Trop (Mars); 2011 Feb; 71(1):25-7. PubMed ID: 21585085
[TBL] [Abstract][Full Text] [Related]
39. [Benznidazole and chronic Chagas disease].
Manigot DA
Medicina (B Aires); 1984; 44(1):105-6. PubMed ID: 6443011
[No Abstract] [Full Text] [Related]
40. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
Morillo CA; Marin-Neto JA; Avezum A; Sosa-Estani S; Rassi A; Rosas F; Villena E; Quiroz R; Bonilla R; Britto C; Guhl F; Velazquez E; Bonilla L; Meeks B; Rao-Melacini P; Pogue J; Mattos A; Lazdins J; Rassi A; Connolly SJ; Yusuf S;
N Engl J Med; 2015 Oct; 373(14):1295-306. PubMed ID: 26323937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
